Exciting Collaboration in Parkinson's Disease Research
In a significant move toward advancing Parkinson's disease therapy, SynuSight Biotech has partnered with ABLi Therapeutics and XingImaging to implement innovative imaging techniques. This collaboration focuses on integrating alpha-synuclein PET imaging into clinical trials examining the efficacy of risvodetinib as a disease-modifying treatment for Parkinson's disease.
Licensing Agreement for Advanced Imaging
SynuSight Biotech has successfully licensed its cutting-edge 18F-FD4 PET imaging technology to both ABLi Therapeutics and XingImaging. This advanced imaging tool is designed to assess the clearance of alpha-synuclein from the brain following treatment with risvodetinib, an innovative therapy targeting fundamental biological processes that contribute to Parkinson's disease.
Enhancing Biomarker Evaluation
Under this agreement, ABLi Therapeutics will utilize the 18F-FD4 tracer in its clinical trials, allowing for real-time visualization of alpha-synuclein pathology within the central nervous system. This is an essential step in creating a comprehensive framework for evaluating the biochemical impacts of risvodetinib, combined with the company’s existing blood and tissue biomarkers.
Clinical Trials to Begin in 2026
ABLi plans to initiate two clinical trials in 2026 utilizing 18F-FD4. The first trial, named ABILITY-PD, will re-enroll participants from a previous Phase 2a study, aiming to evaluate the therapy's impact on various biomarkers over a 12-month period.
Detailed Assessments of Functionality
This project will not only investigate biochemical changes but also collect data on motor, non-motor, and dopamine transporter-related functions to explore how these elements correlate with therapeutic outcomes. The second project, CAMPD, is a Phase 2b/3 trial that will assess the effectiveness of risvodetinib through a double-blind placebo-controlled approach involving up to 500 individuals diagnosed with untreated Parkinson's disease.
Expert Insights on the Collaboration
Roger Fan, CEO of SynuSight, highlighted, "This collaboration marks a pivotal milestone in the FD4 development. We are working diligently to integrate advanced molecular imaging technologies with meticulously designed clinical trials to explore the disease-modifying potential at a deeper level." This sentiment is echoed by Dr. Milton Werner, the Chairman and CEO of ABLi, who emphasized the significance of adding alpha-synuclein PET imaging to their biomarker panel.
Future of Parkinson's Disease Treatment
With a forward-looking approach, Gilles Tamagnan, CEO of XingImaging, expressed optimism about advancing one of the most promising alpha-synuclein PET tracers in conjunction with risvodetinib’s potential benefits, which could drastically reshape the future landscape of Parkinson's disease management.
Understanding Risvodetinib’s Role
Risvodetinib, also known as ABLi-148009, is heralded for its selective inhibition of non-receptor c-Abl kinases. This small-molecule therapeutic, intended for once-daily oral administration, aims to disrupt the biological processes underlying Parkinson's disease and aims to not only halt progression but to also potentially reverse the functional deteriorations associated with the condition.
Proven Efficacy and Advancements
This innovative therapy recently set a benchmark by demonstrating significant improvements in patient quality of life in a random clinical trial while successfully reducing synuclein aggregate pathology among those with untreated Parkinson's disease. With intellectual property coverage secured until after 2036, the focus on risvodetinib appears promising as the medical community anticipates its clinical development to strengthen.
About the Imaging Technology
The 18F-FD4 PET tracer, developed by SynuSight, showcases unique properties that allow it to effectively penetrate the blood-brain barrier, ensuring clarity and precision in imaging alpha-synuclein pathology. With its demonstrated ability to produce consistent high-contrast signals in relevant brain regions, 18F-FD4 is well-positioned to become a pivotal tool in the diagnosis and treatment evaluation of Parkinson’s and related disorders.
Funding and Future Studies
Earlier in 2025, the Michael J. Fox Foundation for Parkinson's Research recognized the significance of 18F-FD4 by awarding a substantial grant to facilitate its clinical development in the U.S. This support affirms the strong scientific rationale and the anticipated impact of this novel imaging biomarker as part of future research endeavors.
Collaborative Efforts Among Industry Leaders
ABLi Therapeutics continues to leverage its expertise in drug design and medicinal chemistry to tackle diseases related to alpha-synuclein. Their approach combines established scientific findings with innovative technologies to create therapeutic solutions with enhanced brain penetration, potency, and safety profiles.
Commitment to Advancing Neurodegenerative Research
XingImaging is dedicated to enhancing pre-clinical and clinical services, focusing on the use of investigational radiotracers. Their commitment to understanding the underlying mechanisms of neurodegenerative disorders is integral in shaping the future of clinical neuroscience and nuclear medicine.
About SynuSight Biotech’s Mission
SynuSight Biotech aims to advance its pioneering efforts in creating diagnostic solutions for neurodegenerative diseases. Utilizing advanced scientific methods and technological innovations, SynuSight is committed to shedding light on conditions that affect millions globally. Their focus on amyloid proteins underscores a commitment to unlocking new therapeutic avenues.
Frequently Asked Questions
What is the focus of the collaboration between SynuSight, ABLi, and XingImaging?
The collaboration is centered around implementing alpha-synuclein PET imaging in clinical trials evaluating risvodetinib for Parkinson's disease treatment.
What is the purpose of the 18F-FD4 PET tracer?
18F-FD4 is designed to visualize alpha-synuclein pathology in the brain, aiding in the evaluation of treatments for neurodegenerative diseases.
When will the clinical trials using 18F-FD4 take place?
The trials are expected to commence in 2026, focusing on the effects of risvodetinib on various biomarkers in participants.
What role does risvodetinib play in treating Parkinson's disease?
Risvodetinib acts as a disease-modifying agent aimed at halting disease progression and potentially reversing functionality loss due to Parkinson's disease.
How has the 18F-FD4 PET tracer been recognized in the research community?
18F-FD4 received a significant grant from the Michael J. Fox Foundation, underscoring its potential as a key imaging tool in Parkinson's disease research.
